Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Trial Profile

Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PADIMAC
  • Most Recent Events

    • 25 Jun 2017 Primary endpoint (2-year PFS for patients who, having achieved CR/VGPR following PAD therapy, do not receive any further treatment) has not been met, according to the abstract presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
    • 02 Apr 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top